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Abstract
Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main
objective was to examine the association between in-hospital death and each routine at-home glucose-lowering
drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for
COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive
and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital
complications and a long-time hospital stay.
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Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s
registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide
cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was
matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the
adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics
after matching. There was considered to be a significant imbalance in the group if a standardized mean difference
> 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and
mixed effect logistic regressions were used when the sample size was ≥ 100.
Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in
monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105
on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on
metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home
glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the
need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or
long-time hospital stays.
Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs
showed no significant association with mortality and adverse outcomes. Given the close relationship between
diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are
needed.
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Background
The novel coronavirus disease 2019 (COVID-19) caused
by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) initially emerged in China in December
2019 and quickly spread around the world, causing a
global pandemic [1].
For patients with COVID-19, diabetes has been re-
ported as one of the most frequent comorbidities, occur-
ring in around 20% of patients [2, 3]. It is well known
that type 2 diabetes mellitus (T2DM) may negatively im-
pact clinical outcomes in patients with COVID-19. Pos-
sible poor outcomes include moderate and severe cases
of COVID-19 disease, a higher rate of hospitalized patients
in intensive care unit (ICU), a higher rate of treatment with
anti-interleukin 6 receptor antibody (tocilizumab), and
higher mortality [4]. Furthermore, it has been reported that
hyperglycemia during COVID-19 infection, and particularly
at hospital admission, has been associated with worse
COVID-19 outcomes and could be a prognostic factor for
worse outcomes in patients with or without T2DM [5, 6].
Indeed, patients with hyperglycemia may experience re-
duced effect of anti-COVID-19 therapies, particularly toci-
lizumab, an anti-interleukin 6 receptor antibody indicated
for patients with moderate-to-severe COVID-19 pneumo-
nia [7]. Thus, not only T2DM status but also the presence
of hyperglycemia could have unfavorable effects on hospital
admission, clinical outcomes, and drug therapy, leading to a
worse prognosis in COVID-19 patients [5, 6].
However, to date, there is no conclusive evidence in
regard to the potential implications on adverse outcomes
of glucose-lowering drugs in patients with COVID-19
[8–11]. In a recent study, the use of oral glucose-lowering
medications (metformin, α-glucosidase, secretagogues,
and dipeptidyl peptidase-4 inhibitors (DPP-4i)) showed
neutral effects on in-hospital mortality and the composite
outcome of poor prognosis defined as progression to se-
vere or critical illness and in-hospital death. In contrast,
insulin usage was associated with a greater risk of poor
prognosis compared to not using it [12]. Other studies
have reported a beneficial effect of metformin and DPP-4i
on clinical outcomes in patients hospitalized with
COVID-19 [13, 14]. The potential effects of these medica-
tions on COVID-19-related pathological mechanisms,
such as systemic inflammation and endothelial dysfunc-
tion, have been proposed as the underlying mechanisms
of possible benefits in reports on mechanistic hypotheses
and preliminary data [10, 15, 16].
We conducted this study based on the premise that
patients with T2DM seem particularly prone to a worse
prognosis if infected by SARS-CoV-2, and in response to
the fact that there is only controversial, limited evidence
on the role of glucose-lowering drugs on clinical adverse
outcomes. Our main objective was to examine the asso-
ciation between in-hospital death and each routine at-
home glucose-lowering drug both individually and in
combination with metformin in patients with T2DM ad-
mitted for COVID-19. We also evaluated their associ-
ation with the composite outcome of need for ICU
admission, invasive and non-invasive mechanical ventila-
tion, or in-hospital death as well as on the development
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of in-hospital complications and a long-time hospital
stay.
Methods
Study design and population
We selected all patients with T2DM included in the
Spanish Society of Internal Medicine’s registry of
COVID-19 patients (SEMI-COVID-19 Registry) [17]
from March 1, 2020, to the study’s cutoff date of July 19,
2020. The SEMI-COVID-19 Registry is an ongoing, ob-
servational, multicenter, nationwide cohort of patients
admitted for COVID-19 in Spain from March 1, 2020,
whose main objective is to obtain detailed information
on the epidemiology, clinical progress, and treatment re-
ceived by patients with COVID-19 in real-world clinical
practice at admission and during hospitalization. It
retrospectively compiles sociodemographic variables,
previous medical history, routine at-home treatments,
clinical presentation, the patient’s clinical condition (in-
cluding the degree of functional dependence as evalu-
ated by the Barthel Index [18] and the presence of
comorbidities as evaluated by the Charlson Comorbidity
Index [19]), laboratory test results (blood gas analysis,
complete blood count, coagulation tests, glucose, cre-
atinine, urea, lactate dehydrogenase, alanine aminotrans-
ferase, aspartate aminotransferase, alkaline phosphatase,
bilirubin, sodium, potassium, triglycerides, creatine kin-
ase, ferritin, lactic acid, c-reactive protein, procalcitonin,
interleukin 6, d-dimer, troponin, albumin), radiological
findings (chest X-ray, chest-computerized tomography
scan, lung ultrasound), clinical management, hospital
complications, hospital stay, and in-hospital death from
the first admission for COVID-19 of patients who are
aged 18 years of age or older.
An online electronic data capture system was devel-
oped for the registry, including a database manager
along with procedures for the verification of data and
contrasting of information against the original medical
record in order to ensure the best possible quality of
data collection. The database platform is hosted on a se-
cure server. All information contained in the database,
the configuration of the information within the database,
and the database itself are fully encrypted. Every client-
server data transfer is encrypted through a valid TLS
certificate. Daily backups are performed in order to en-
sure data integrity.
A diagnosis of T2DM was ascertained either through a
T2DM diagnosis in medical records or a self-reported
diagnosis confirmed by medical records reviewed by
physicians. T2DM was defined according to the most re-
cent American Diabetes Association guidelines [20].
In-hospital complications include the onset of at least
one of the following: secondary bacterial pneumonia,
acute respiratory distress syndrome, acute heart failure,
arrhythmia, acute coronary syndrome, myocarditis, epi-
leptic seizures, stroke, shock, sepsis, acute kidney failure,
disseminated intravascular coagulation, venous thrombo-
embolism, multiple organ dysfunction syndrome, acute
limb ischemia, ICU admission, and need for ventilation
support, including invasive and non-invasive mechanical
ventilation or high-flow oxygen therapy. A long hospital
stay was defined as hospitalization longer than the me-
dian length of stay in days for all patients included in
this study.
Diagnosis and severity grade of COVID-19 disease
The presence of COVID-19 in respiratory specimens
was established by RNA detection of SARS-CoV-2 using
real-time reverse transcription-polymerase chain reac-
tion methods as indicated by the international literature
on COVID-19 infection [1]. Diagnostic testing for
SARS-CoV-2 was performed in appropriately equipped
laboratories by staff trained in the relevant technical and
safety procedures. The COVID-19 pneumonia severity
grade was established according to the patient’s clinical
condition: mild grade (symptoms without evidence of
pneumonia or hypoxia), moderate grade (clinical signs of
pneumonia but no signs of severe pneumonia, including
basal oxygen saturation ≥ 92%), severe grade (clinical
signs of pneumonia plus one of the following: basal oxy-
gen saturation < 92%, resting respiratory rate > 30
breaths/min, severe respiratory distress), and critical
grade (sepsis or shock with acute respiratory distress
syndrome and/or multiple organ dysfunction or failure).
Study outcomes
The primary outcome was in-hospital death according
to each at-home glucose-lowering drug in monotherapy
or in dual therapy with metformin. Secondary outcomes
were the following: first, a composite outcome including
the need for ICU admission, invasive and non-invasive
mechanical ventilation, or in-hospital death; second, in-
hospital complications; and third, a long hospital stay.
Statistical analysis
The characteristics of patients with T2DM included in
the registry were analyzed using descriptive statistics.
Continuous and categorical variables were expressed as
means ± standard deviation and as absolute value and
percentage, respectively. The differences between the
groups were determined using the two-sample Student’s
t test or the Mann-Whitney-Wilcoxon rank-sum test for
continuous variables and Pearson’s chi-squared test for
categorical variables. Values were considered to be sta-
tistically significant when p < 0.05.
We grouped patients according to glucose-lowering
drugs in monotherapy and in combination with metfor-
min. In order to match each patient in one of these
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groups with a patient of another group receiving other
glucose-lowering drugs in a 1:1 manner, propensity
scores using nearest neighbor matching with a caliper of
0.1 and a greedy matching algorithm were used. The
probability of a patient being treated with one glucose-
lowering drug as opposed to other glucose-lowering
drugs was estimated using a logistic regression model
that included variables that could have affected the out-
comes as independent variables (age; gender; history of
smoking, hypertension; dyslipidemia; chronic kidney dis-
ease; cerebrovascular disease; chronic obstructive pul-
monary disease; atrial fibrillation; coronary artery
disease; heart failure; obesity; dementia; Barthel Index
score; and Charlson Comorbidity Index score; treatment
with angiotensin-converting enzyme inhibitor, angioten-
sin II receptor blocker, anticoagulant, and statin; admis-
sion blood glucose; serum creatinine; and transaminase
levels). In order to assess the adequacy of propensity
matching, we used the standardized mean difference
found in patient characteristics after matching. There
was considered to be a significant imbalance in the
group if a standardized mean difference between base-
line variables of greater than 10% was found.
According to the findings of Austin [21], the statistical
models for paired samples are preferable to models for
the analysis of independent samples. For this reason, in
order to evaluate the association between treatment and
study outcomes, both conditional logit and mixed effect
(matched pairs as random effects) logistic regressions
were used. In case the sample size was smaller than 100,
the McNemar test for matched data was performed to
evaluate the association. We also performed univariate
and multivariate logistic regression models adjusted with
confounding variables in order to estimate the treatment
effect using the totality of the data, as a sensitivity ana-
lysis. Statistical analyses were performed using the R
software, version 3.6.2.
Results
Baseline clinical variables and treatments
A total of 2666 patients with T2DM admitted for
COVID-19 were included in this study. Baseline sociode-
mographic, clinical, and therapeutic variables are shown
in Table 1. In regard to glucose-lowering drugs, metfor-
min was the most frequently used (60.8%), followed by
DPP-4i (30.2%), insulin (27.6%), sodium-glucose cotran-
sporter 2 inhibitor (SGLT-2i) (11.3%), and glucagon-like
peptide-1 receptor agonist (GLP-1RA) (4.8%).
Of the total number of patients, 1297 (48.6%) were
treated with glucose-lowering drugs in monotherapy
(825 with metformin (63.6%), 180 with DPP-4i (13.9%),
and 292 with insulin (22.5%)). Dual therapy of metfor-
min in combination with other glucose-lowering drugs
was used in 465 patients (17.4%) (288 with metformin
plus DPP-4i (61.9%), 67 metformin plus SGLT-2i
(14.4%), and 110 metformin plus insulin (23.7%)). Fol-
lowing 1:1 propensity score matching of each glucose-
lowering drug alone or in combination with metformin
versus the other glucose-lowering drugs, 249 patients
were included in the metformin group, 105 in the DPP-
4i group, 129 in the insulin group, 127 in the metformin
plus DPP-4i group, 34 in the metformin plus SGLT-2i
group, and 67 in the metformin plus insulin group. No
patients were identified with GLP-1RA alone, SGLT-2i
alone, or metformin plus GLP-1RA. A flow chart for
pre- and post-propensity score matching showing pa-
tients in each compared group can be found in Fig. 1.
Pre- and post-propensity matching characteristics
The pre- and post-propensity score matching of the
baseline sociodemographic and clinical characteristics of
each glucose-lowering drug alone or in combination
with metformin versus the other glucose-lowering drugs
used by patients before hospitalization for COVID-19
are shown in Additional file 1: Table S1; Additional file 2:
Table S2; Additional file 3: Table S3; Additional file 4:
Table S4; Additional file 5: Table S5; and Additional file 6:
Table S6. After propensity matching, the groups were
well-balanced, and only negligible differences were ob-
served (standardized mean difference ≤ 0.1).
Associations between treatments and study outcomes
After propensity score matching, no differences were
found in in-hospital deaths; the composite outcome of
need for ICU admission, invasive and non-invasive
mechanical ventilation, or in-hospital death; in-hospital
complications; and a long-time hospital stay according
to the glucose-lowering drug used. None of the at-home
glucose-lowering drugs analyzed showed significant as-
sociation with study outcomes after applying both the
conditional logit and mixed effect logistic regression if
the sample size was ≥ 100 or McNemar test if the sample
size was < 100. The association between each glucose-
lowering drug group and the study outcomes after pro-
pensity matching is shown in Tables 2 and 3.
Before matching, patients treated at home with met-
formin in monotherapy, compared to patients who were
treated with other glucose-lowering drugs, had a lower
rate of in-hospital deaths (29.6% vs 36.8%, p = 0.005); the
composite outcome of ICU admission, mechanical venti-
lation, or in-hospital death (35.8% vs 41.9%, p = 0.023);
and in-hospital complications (52.7% vs 59.4%, p =
0.013). A lower in-hospital death rate was also found in
patients with metformin plus DPP-4i (27.8% vs 35.4%,
p = 0.044) and in patients with metformin plus SGLT-2i
(19.4% vs 39.1%, p = 0.003). On the other hand, a higher
rate of in-hospital deaths was observed among patients
with DPP-4i alone and insulin alone (41.7% vs 31.2%,
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p = 0.007; 38% vs 29.6%, p = 0.007, respectively). Patients
with insulin also had a higher rate of the composite out-
come of the need for ICU admission, mechanical ventila-
tion, or in-hospital death (42.8% vs 36.2%, p = 0.039).
Patients treated with metformin and insulin were found
to have higher rates of in-hospital complications (66.4%
vs 55.0%, p = 0.030).
On the univariate models, metformin was significantly
associated with a lower rate of in-hospital deaths (odds
ratio (OR) 0.73, 95% confidence interval (CI) 0.58–0.90,
p = 0.004); the need for ICU admission, mechanical ven-
tilation, or in-hospital death (OR 0.78, 95% CI 0.63–
0.96, p = 0.020); and in-hospital complications (OR 0.76,
95% CI 0.62–0.94, p = 0.011). Metformin in combination
with DPP-4i was associated with a lower in-hospital
death rate (OR 0.70, 95% CI 0.50–0.98, p = 0.036).
Otherwise, DPP-4i and insulin were associated with
higher in-hospital deaths (OR 1.56, 95% CI 1.13–2.14,
p = 0.006; OR 1.45, 95% CI 1.11–1.88, p = 0.006; respect-
ively). The composite outcome of the need for ICU ad-
mission, mechanical ventilation, or in-hospital death was
also higher in patients on insulin (OR 1.32, 95% CI
1.02–1.71, p = 0.033). These associations were not found
when models were fully adjusted using multivariate lo-
gistic regression. The association between each glucose-
lowering drug group and the study outcomes before pro-
pensity score matching is shown in Tables 4 and 5.
Discussion
Our study found that none of the at-home glucose-
lowering drugs analyzed (metformin, DPP-4i, insulin,
metformin plus DPP-4i, metformin plus SGLT-2i, and
metformin plus insulin) showed a significant association
with in-hospital deaths; the composite outcome of the
need for ICU, mechanical ventilation, or in-hospital
death; in-hospital complications; or a long-time hospital
stay.
Currently, only limited evidence is available on the
role of glucose-lowering drugs in adverse clinical out-
comes. Recently, a study conducted by Chen et al. [12]
focused on the impact of glucose-lowering medications
Table 1 Baseline sociodemographic clinical and therapeutic
characteristics of patients with type 2 diabetes mellitus
hospitalized for coronavirus disease 2019
Variables n = 2666
Age (years) 74.9 ± 8.4
Male gender 1647 (61.9%)
Obesity 766 (31.6%)
Admission blood glucose (mg/dL) 153 ± 45.7
Admission serum creatinine (mg/dL) 1.03 ± 0.23
Admission aspartate aminotransferase (U/L) 31 ± 8






Angiotensin-converting enzyme inhibitor 724 (27.4%)




History of smoking 955 (35.8%)
Hypertension 2026 (76.2%)
Dyslipidemia 1730 (65.0%)
Chronic kidney disease 352 (13.2%)
Atrial fibrillation 444 (16.7%)
Coronary artery disease 610 (22.9%)
Heart failure 445 (16.7%)
Chronic obstructive pulmonary disease 346 (13.0%)





Moderate-severe functional dependence 636 (24.2%)











Table 1 Baseline sociodemographic clinical and therapeutic
characteristics of patients with type 2 diabetes mellitus
hospitalized for coronavirus disease 2019 (Continued)
Variables n = 2666
Corticosteroids 1186 (44.5%)
Tocilizumab 215 (8.1%)
Values are shown as mean ± standard deviations, absolute values,
and percentages
The degree of functional dependence was assessed using the Barthel Index.
The presence of comorbidities was assessed using the Charlson
Comorbidity Index
DPP-4i dipeptidyl peptidase-4 inhibitors, GLP-1RA glucagon-like peptide-1
receptor agonist, mg/dL milligram/deciliter, SGLT-2i sodium-glucose
cotransporter 2 inhibitor, U/L unit/liter
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on the clinical outcomes of patients with diabetes and
COVID-19, showing that insulin users had a greater risk
of a composite outcome of progression to severe or crit-
ical illness and in-hospital death compared with non-
insulin users (OR 3.58, 95% CI 1.37–9.35, p = 0.009).
However, none of the glucose-lowering medications
(metformin, DPP-4i, α-glucosidase, secretagogues, and
insulin) was associated with in-hospital deaths. In our
study, all glucose-lowering medications evaluated, in-
cluding oral drugs and insulin, had no significant associ-
ation with in-hospital adverse outcomes in patients
admitted for COVID-19. The differences in the defini-
tions of the outcomes of clinical complications during
the hospitalization, the methodology used, and the sam-
ple size could explain the difference found regarding the
role of insulin. We included an important number of pa-
tients taking glucose-lowering drugs and performed a
propensity score matching that included variables that
could affect the treatment choice or adverse outcomes
as independent variables.
Two observational studies have specifically evaluated
the role of metformin and DPP-4i in patients admitted
for COVID-19 [13, 14]. The study focused on metfor-
min, conducted by Bramante et al. [13] in the USA,
found no significant reduction in in-hospital mortality in
the overall sample, which is in line with our results.
However, when a subgroup analysis was performed,
women with obesity and T2DM who used metformin
were observed to have a significantly lower mortality
rate. Metformin has been proposed to reduce levels of
IL-10, IL-6, and TNFα—important mediators in macro-
phage activation and cytokine release; improves neutrophil/
lymphocyte ratio; stabilizes mast cells; decreases throm-
bosis; and improves endothelial function, thus reducing the
adverse impacts of mortality and complication in patients
with COVID-19 [13, 22–27]. In the study of Rhee et al. [14]
from Korea, protective effects against severe/lethal cases
were shown in patients with T2DM who used DPP-4i in
monotherapy or in combination with renin-angiotensin
system blockers after adjusting for age, gender, comor-
bidity, and medications [14]. It is known that DPP-4i
have anti-fibrotic activity and modulate inflammation
and that these properties could be helpful in reducing
the progression towards a hyperinflammatory state as-
sociated with severe COVID-19 [14, 28, 29]. All these
major inflammatory mechanisms observed in some
COVID-19 patients suggest that the endothelium could
be a key target organ in COVID-19 infection [30]. The
role of renin-angiotensin system blockers in hyperten-
sive patients with COVID-19 has also been widely dis-
cussed [31]. Although hypertension has been associated
with a higher risk of mortality, recent studies have
shown that previous treatment with angiotensin-
converting enzyme inhibitors and angiotensin II recep-
tor blockers did not alter the outcomes in hypertensive
patients [31, 32]. In our study, no significant associa-
tions with adverse clinical outcomes were found among
users of DPP-4i and users of the other glucose-lowering
drugs. This difference could be explained by the differ-
ent methodology used in our study, which includes an
important adjustment using a propensity score matching
in order to compare the two groups of glucose-lowering
drugs, as well as the differences in the baseline characteris-
tics, with older patients and higher comorbidity found in
Fig. 1 Flow chart for pre- and post-propensity score matching indicating the number of patients in each compared group. COVID-19, coronavirus
disease 2019; DPP-4i, dipeptidyl peptidase-4 inhibitors; GLD, glucose-lowering drugs; GLP-1RA, glucagon-like peptide-1 receptor agonists; SGLT-2i,
sodium-glucose transporter 2 inhibitors; T2DM, type 2 diabetes mellitus
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Table 2 Association between metformin, dipeptidyl peptidase-4 inhibitors, insulin, and metformin plus dipeptidyl peptidase-4
inhibitors and study outcomes after propensity score matching










In-hospital deaths 79 (31.7%) 79 (31.7%) 1.000 1.15 (0.78–1.71) 0.482 1.16 (0.78–1.72) 0.482
ICU admission, mechanical ventilation,
or in-hospital death
91 (36.5%) 88 (35.4%) 0.852 1.05 (0.73–1.51) 0.780 1.05 (0.73–1.52) 0.779
In-hospital complications 146 (58.6%) 139 (55.8%) 0.587 1.18 (0.81–1.72) 0.392 1.17 (0.81–1.70) 0.398
Long-time hospital stay 59 (23.7%) 45 (18.1%) 0.152 1.49 (0.95–2.31) 0.079 1.49 (0.96–2.33) 0.075
DPP-4i (n = 105) Other GLD
(n = 105)
p value
In-hospital deaths 41 (39.0%) 44 (41.9%) 0.779 1.05 (0.66–2.13) 0.521 1.05 (0.67–2.11) 0.562
ICU admission, mechanical ventilation,
or in-hospital death
45 (42.9%) 42 (40.0%) 0.780 1.12 (0.65–1.92) 0.680 1.12 (0.65–1.95) 0.675
In-hospital complications 66 (62.9%) 70 (66.7%) 0.665 0.94 (0.67–2.12) 0.480 0.94 (0.67–2.13) 0.481
Long-time hospital stay 23 (21.9%) 24 (22.9%) 1.000 0.83 (0.38–1.46) 0.400 0.84 (0.39–1.46) 0.406
Insulin (n = 129) Other GLD
(n = 129)
p value
In-hospital deaths 51 (39.5%) 46 (35.7%) 0.607 1.15 (0.65–1.97) 0.590 1.15 (0.65–1.97) 0.598
ICU admission, mechanical ventilation,
or in-hospital death
57 (44.2%) 54 (41.9%) 0.802 1.10 (0.67–1.80) 0.710 1.10 (0.67–1.81) 0.706
In-hospital complications 49 (38.9%) 46 (35.7%) 0.796 1.00 (0.58–1.67) 0.930 1.00 (0.57–1.67) 0.912






In-hospital deaths 29 (22.8%) 37 (29.1%) 0.317 0.73 (0.40–1.28) 0.270 0.72 (0.39–1.27) 0.251
ICU admission, mechanical ventilation,
or in-hospital death
40 (31.5%) 45 (35.4%) 0.592 0.84 (0.50–1.41) 0.510 0.84 (0.49–1.41) 0.503
In-hospital complications 67 (52.8%) 70 (55.1%) 0.801 0.87 (0.51–1.46) 0.596 0.86 (0.50–1.47) 0.592
Long-time hospital stay 29 (22.8%) 26 (20.5%) 0.761 1.17 (0.62–2.23) 0.627 1.17 (0.62–2.19) 0.632
Data are shown as absolute values and percentages. A significant imbalance in the group was considered if a standardized mean difference between baseline
variables of greater than 10% was found. Values were considered to be statistically significant when p < 0.05
DPP-4i dipeptidyl peptidase-4 inhibitors, GLD glucose-lowering drugs, ICU intensive care unit, OR odds ratio, 95% CI 95% confidence interval
Table 3 Association between metformin plus sodium-glucose transporter 2 inhibitors and metformin plus insulin and study
outcomes after propensity score matching
Outcomes Treatment groups McNemar test
Metformin + SGLT-2i (n = 34) Other GLD (n = 34) p value
In-hospital deaths 6 (17.6%) 10 (29.4%) 0.391 1.000
ICU admission, mechanical ventilation, or in-hospital death 10 (29.4%) 11 (32.4%) 0.987 0.965
In-hospital complications 19 (55.9%) 22 (64.7%) 0.620 0.201
Long-time hospital stay 6 (17.6%) 4 (11.8%) 0.732 0.838
Metformin + insulin (n = 67) Other GLD (n = 67) p value
In-hospital deaths 24 (35.8%) 23 (34.3%) 1.000 0.521
ICU admission, mechanical ventilation, or in-hospital death 46 (68.7%) 36 (53.7%) 0.112 0.111
In-hospital complications 44 (65.7%) 36 (53.7%) 0.218 0.480
Long-time hospital stay 15 (22.4%) 13 (19.4%) 0.832 0.870
Data are shown as absolute values and percentages. Values were considered to be statistically significant when p < 0.05
GLD glucose-lowering drugs, ICU intensive care unit, SGLT-2i sodium-glucose transporter 2 inhibitors
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Table 4 Association between metformin, dipeptidyl peptidase-4 inhibitors, insulin, and metformin plus dipeptidyl peptidase-4
inhibitors and study outcomes before propensity score matching
Outcomes Treatment groups Univariate model Multivariate model
OR (95% CI) p value OR (95% CI) p value
Metformin (n = 825) Other GLD
(n = 663)
p value
In-hospital deaths 244 (29.6%) 244 (36.8%) 0.005 0.73 (0.58–0.90) 0.004 1.10 (0.76–1.60) 0.616
ICU admission, mechanical ventilation,
or in-hospital death
295 (35.8%) 278 (41.9%) 0.023 0.78 (0.63–0.96) 0.020 1.03 (0.73–1.44) 0.883
In-hospital complications 435 (52.7%) 394 (59.4%) 0.013 0.76 (0.62–0.94) 0.011 1.08 (0.77–1.50) 0.666
Long-time hospital stay 195 (23.6%) 149 (22.5%) 0.584 1.08 (0.85–1.38) 0.542 1.41 (0.96–2.09) 0.080
DPP-4i (n = 180) Other GLD
(n = 1409)
p value
In-hospital deaths 75 (41.7%) 440 (31.2%) 0.007 1.56 (1.13–2.14) 0.006 1.39 (0.64–1.67) 0.876
ICU admission, mechanical ventilation,
or in-hospital death
80 (44.4%) 531 (37.7%) 0.119 1.30 (0.95–1.78) 0.102 0.97 (0.61–1.52) 0.890
In-hospital complications 113 (62.8%) 775 (55.0%) 0.104 1.33 (0.96–1.84) 0.089 0.95 (0.59–1.54) 0.842
Long-time hospital stay 35 (19.4%) 321 (22.8%) 0.333 0.81 (0.54–1.18) 0.288 0.90 (0.52–1.52) 0.703
Insulin (n = 292) Other GLD (n = 1458) p value
In-hospital deaths 111 (38.0%) 431 (29.6%) 0.007 1.45 (1.11–1.88) 0.006 1.11 (0.70–1.75) 0.652
ICU admission, mechanical ventilation,
or in-hospital death
125 (42.8%) 528 (36.2%) 0.039 1.32 (1.02–1.71) 0.033 1.09 (0.71–1.66) 0.699
In-hospital complications 170 (58.2%) 786 (53.9%) 0.143 1.23 (0.95–1.60) 0.126 0.96 (0.62–1.47) 0.834






In-hospital deaths 80 (27.8%) 136 (35.4%) 0.044 0.70 (0.50–0.98) 0.036 0.71 (0.40–1.28) 0.257
ICU admission, mechanical ventilation,
or in-hospital death
104 (36.1%) 159 (41.4%) 0.159 0.79 (0.57–1.08) 0.137 0.82 (0.50–1.36) 0.452
In-hospital complications 160 (55.6%) 226 (58.9%) 0.304 0.84 (0.61–1.15) 0.268 1.01 (0.63–1.62) 0.975
Long-time hospital stay 71 (24.7%) 95 (24.7%) 1.000 1.00 (0.71–1.44) 0.963 1.42 (0.82–2.47) 0.217
Data are shown as absolute values and percentages. Values were considered to be statistically significant when p < 0.05
DPP-4i dipeptidyl peptidase-4 inhibitors, GLD glucose-lowering drugs, ICU intensive care unit, OR odds ratio, 95% CI 95% confidence interval
Table 5 Association between metformin plus sodium-glucose transporter 2 inhibitors and metformin plus insulin and study
outcomes before propensity score matching
Outcomes Treatment groups
Metformin + SGLT-2i (n = 67) Other GLD (n = 583) p value
In-hospital deaths 13 (19.4%) 228 (39.1%) 0.003
ICU admission, mechanical ventilation, or in-hospital death 35 (52.2%) 375 (64.3%) 0.051
In-hospital complications 33 (49.3%) 351 (60.2%) 0.132
Long-time hospital stay 8 (11.9%) 130 (22.3%) 0.087
Metformin + insulin (n = 110) Other GLD (n = 1375) p value
In-hospital deaths 43 (39.1%) 445 (32.4%) 0.175
ICU admission, mechanical ventilation, or in-hospital death 76 (69.1%) 810 (58.9%) 0.084
In-hospital complications 73 (66.4%) 756 (55.0%) 0.030
Long-time hospital stay 21 (19.1%) 320 (23.3%) 0.360
Data are shown as absolute values and percentages. Values were considered to be statistically significant when p < 0.05
GLD glucose-lowering drugs, ICU intensive care unit, SGLT-2i sodium-glucose transporter 2 inhibitors
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our study compared with Rhee et al.’s study (mean age of
74.9 ± 8.4 vs 63.7 ± 12.2 years old).
Other glucose-lowering treatments in our study, such as
metformin in combination with SGLT-2i or with insulin,
showed no significant differences compared with the other
glucose-lowering treatments. No propensity score match-
ing was performed for these two comparisons due to the
small number of patients in these treatment groups, so no
solid conclusions may be drawn. To our knowledge, no
evidence exists about the role of SGLT-2i on adverse out-
comes in patients with COVID-19. A hypothetical anti-
viral effect of SGLT-2i has been suggested, as these agents
can increase lactate concentrations and decrease intracel-
lular pH, which could reduce the viral load [33].
Our findings are important because they provide valuable
information on the role of at-home glucose-lowering drugs
on adverse outcomes in patients with T2DM admitted for
COVID-19. In addition, this is the first study to report the
role of each glucose-lowering drugs alone or in combination
with metformin compared to the other glucose-lowering
drugs after a robust adjustment using a wide number of
confounding variables. Furthermore, data were collected in
a large multicenter, nationwide study. Nevertheless, these re-
sults should be considered within the context of several po-
tential limitations. Despite the propensity matching analysis
performed and due to the fact that the data were obtained
retrospectively via medical records from the electronic med-
ical record system, the possible effects of unmeasured con-
founding factors cannot be excluded. In addition, some
glucose-lowering drug group comparisons had a small num-
ber of patients after propensity score matching that could be
an explanation for the lack of significant differences. No
other intermediate adverse outcomes were explored due to
their reduced number. Furthermore, we did not record the
characteristics of T2DM, such as glycemic control before
hospitalization, duration of diabetes, blood glucose levels
during the hospitalization, or in-hospital anti-hyperglycemic
management. Lastly, the data provided about at-home
glucose-lowering drugs did not include information on
treatment adherence or treatment duration.
Conclusions
Our study found that the at-home use of metformin, DPP-
4i, insulin, metformin plus DPP-4i, metformin plus SGLT-
2i, and metformin plus insulin showed no significant associ-
ation with in-hospital deaths; the composite outcome of
need for ICU admission, mechanical ventilation, or in-
hospital death; in-hospital complications; or long-time hos-
pital stay in patients with T2DM admitted for COVID-19.
Given the large number of patients with T2DM and
COVID-19 infection, the ominous relationship between
these pathologies, and the limited evidence on the role of
glucose-lowering drugs, prospective studies are needed.
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